Bearing in mind the possible impact of the immune system on chemotherapy response, the aim of the current study was to analyze the potential use of pretreatment circulating eosinophil counts as a biomarker of therapy response in TNBC and HR−/HER2+ breast cancers treated with NAC. The gene discussed is ERBB2; the disease is breast cancer.